Refractory relapsing polychondritis in a child treated with antiCD20 monoclonal antibody (rituximab): First case report

Abdwani, Reem; Kolethekkat, Arif Ali; Al-Abri, Rashid

doi:10.1016/j.ijporl.2012.03.026

Cited by 18 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Due to airway inflammation and collapse, coughing is less effective at clearing secretions. According to several reports, between 10% and 50% of individuals with RP die from these respiratory problems, which are primarily tracheal collapse and infections [6,13].…”

Section: Discussionmentioning

confidence: 99%

“…The goal of treatment is to control the acute inflammatory crisis and the long-term suppression of the immune-mediated pathogenetic pathways [1]. Generally, corticosteroids are the primary treatment, although immunosuppressive medications such cyclophosphamide, cyclosporine A, azathioprine, methotrexate, and mycophenolate mofetil can be used in individuals with persistent or refractory illness [1,13]. Tumor necrosis factor (TNF) antagonists, interleukin 1 (IL-1) receptor antagonists, anti-IL-6 receptor antibodies, and anti-cluster of differentiation 20 (CD20) monoclonal antibodies are a few biological modifiers that have been used in recent research to ameliorate symptoms with various degrees of success [6,13].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pediatric-Onset Relapsing Polychondritis With Otolaryngeal Manifestations

Figaro,

Juman

et al. 2023

Cureus

View full text Add to dashboard Cite

Relapsing polychondritis (RP) is a rare autoimmune disease that can present with various clinical manifestations. Among the affected sites, the ear, nose, and throat cartilages are frequently involved, often leading to subtle and episodic symptoms that can be challenging to diagnose. A high index of suspicion is necessary for the early identification of these subtle signs, which can aid in early diagnosis and prompt management. In this report, we present a rare case of pediatric-onset relapsing polychondritis that was initially misdiagnosed as laryngotracheobronchitis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Pediatric-Onset Relapsing Polychondritis With Otolaryngeal Manifestations

Figaro,

Juman

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Currently, the use of biological medications has been discussed as part of the treatment for RP, especially in cases when treatment with corticosteroids fails [2, 17, 18], and the use of these molecules has expanded into the treatment of other autoimmune comorbidities [19]. However, two cases of RP during TNF-blocker therapy were reported in Spain in 2011 [20].…”

Section: Discussionmentioning

confidence: 99%

Relapsing Polychondritis in a Patient with Ankylosing Spondylitis Using Etanercept

Azevedo

Galli

Kleinfelder

et al. 2014

Case Reports in Rheumatology

View full text Add to dashboard Cite

Relapsing polychondritis (RP) is an autoimmune disease characterized by recurrent episodes of inflammation and progressive destruction of cartilaginous tissues, especially of the ears, nose, joints, and tracheobronchial tree. Its etiology is not well understood, but some studies have linked its pathophysiology with autoimmune disease and autoantibody production. We described a case of a 46-year-old male patient with ankylosing spondylitis who developed RP after the use of etanercept. Few similar cases have been described in the literature. However, they show a possible association between the use of biological inhibitors of tumor necrosis factor (anti-TNFα), which potentially produces autoantibodies, and the development of RP. The treatment was based on data in the literature and included the cessation of biological therapy and the addition of corticosteroids with substantial improvement.

show abstract

“…Medical management of RP consist in control the inflammatory process with steroids combined with methotexate, azatriopine or cyclophosphamide. Some studies propose the use of immunomodularity therapies as etanercept, infliximab or rituximab [ 39 , 40 ]. Interventional bronchoscopy procedures such as dilating, and stenting may help in specific cases [ 41 ].…”

Section: Etiologymentioning

confidence: 99%

Central airway obstruction: is it time to move forward?

et al. 2022

View full text Add to dashboard Cite

Introduction Central airway obstruction (CAO) represents a pathological condition that can lead to airflow limitation of the trachea, main stem bronchi, bronchus intermedius or lobar bronchus. Main body It is a common clinical situation consensually considered under-diagnosed. Management of patients with CAO can be difficult and deciding on the best treatment approach represents a medical challenge. This work intends to review CAO classifications, causes, treatments and its therapeutic limitations, approaching benign and malign presentations. Three illustrative cases are further presented, supporting the clinical problem under review. Conclusion Management of CAO still remains a challenge. The available options are not always effective nor free from complications. A new generation of costume-tailored airway stents, associated with stem cell-based therapy, could be an option in specific clinical situations.

show abstract

Refractory relapsing polychondritis in a child treated with antiCD20 monoclonal antibody (rituximab): First case report

Cited by 18 publications

References 24 publications

Pediatric-Onset Relapsing Polychondritis With Otolaryngeal Manifestations

Pediatric-Onset Relapsing Polychondritis With Otolaryngeal Manifestations

Relapsing Polychondritis in a Patient with Ankylosing Spondylitis Using Etanercept

Central airway obstruction: is it time to move forward?

Contact Info

Product

Resources

About